

Index

A

17-AAG, 17, 18, 111, 112, 114–118, 123–128
Activation function 1 (AF-1), 3, 4, 6, 9, 88, 102, 148, 149, 179
Acute myeloid leukaemia, 98, 126
Adhesion, 10, 70, 86, 90, 140–142, 144, 147, 150, 151
AF-2, 3, 4, 6, 64
AG1478, 182
AIB1, 4, 8, 15, 30–32, 34, 102, 177
AKT, 4, 5, 8–12, 14–18, 32, 33, 64, 68, 113, 123, 124, 127, 129, 143, 144, 148, 166, 168–170, 178–180, 187, 188
Aldehyde dehydrogenase, 100
Anastrozole, 181, 182, 185, 186
Antihormone, 2, 63, 64, 66–72, 74–77, 139–152
Aromatase inhibitor, 5, 28, 64, 169, 176, 178, 181, 182, 187
5-aza-cytidine, 42
AZD0530, 17, 150
5AZA (5 aza-2'-deoxycytidine), 15, 18, 74, 167

B

Beta-catenin, 14, 142, 143, 151
Bortezomib, 116, 127, 128

C

Cancer stem-like cell (CSCs), 97–101, 103–106
CCT018159, 118, 119
CD44, 1–03, 15, 16, 70, 99–101, 143, 145, 146, 152
CDK10, 13, 16, 161, 162, 165–167, 170
Cell cycle, 3–5, 11, 15, 16, 40, 118, 119, 124, 151, 165, 166, 169
ER expression and, 40
Cell membrane, 3, 4, 6, 8–10, 14

Cell morphology, 141, 142
C-erbB-2, 42, 43, 55
Chemoattractant, 88
Chromatin immunoprecipitation, 9, 28
Chromatin IP (ChIP), 9, 28–30, 165
Chromatin remodeling, 29, 30, 76
Clinical trials, 111, 116, 117, 119, 127, 128, 167–169, 175, 181, 183, 186
C-Met, 15, 18, 69, 70, 72, 90, 91, 144–146, 152
Coactivators, of ER, 27, 29, 30
Combination therapy, 104, 106, 167, 175, 178, 186
Compensatory signaling, 17, 64, 75
Conditioned medium, 85, 87, 90–92, 144, 151, 152
CpG islands, 13, 15, 42, 73, 74
Cross-talk, 2, 5, 7–9, 12, 16, 27, 32, 64, 65, 68, 85, 89–91, 93, 140, 147, 149, 178–180
ER and growth factor pathways, 12, 16, 147, 178, 180
growth factor-ER, 12, 149
Cytokines, 14, 32, 86–88, 90, 93, 144, 146, 170, 178

D

Demethylating agent, 42, 177
DNA binding proteins, 27
Ductal carcinoma *in situ*, (DCIS), 41

E

E-cadherin, 71, 72, 142, 143, 147
EFFECT trials, 181
Endocrine resistance, 2, 8, 9, 12–18, 28, 32–34, 66, 85, 86, 89, 91–93, 97, 102, 104, 139–152, 175–179, 181, 187–189
acquired, 2, 28, 142, 143, 147, 150, 177, 189
DNA hypermethylation and, 14
DNA hypomethylation and, 14

- ER independent, 12
Prevention, 16
zinc transporters and, 14
- Endocrine therapy, 5, 16, 18, 31, 32, 73, 89, 97, 101–103, 105, 139–141, 146, 152, 161–163, 165–170, 175–183, 186–189
- Endothelial cells, 13, 86, 104, 119, 151
- Epidermal growth factor (EGF), 9, 32, 43, 44, 103, 149, 179, 187
- Epidermal growth factor receptor (EGFR), 5, 7–10, 12–15, 17, 18, 32, 39, 42–45, 50, 52, 53, 55, 63–65, 67–70, 74–76, 90, 91, 103, 105, 113, 128, 140, 143, 146, 148–150, 166, 167, 169, 177, 179, 180, 182, 183, 186
- Epigenetic silencing, 73, 74, 167
- Epithelial to mesenchymal transition (EMT), 15, 71, 142, 143, 145, 147
- ERK, 5, 10, 32, 39, 43–45, 123, 148, 151, 165, 166
- Erlotinib, 166, 180, 182, 183, 185
- Estrogen receptor (ER), 1–18, 28–34, 39–55, 63–69, 71–75, 86, 88–92, 101–103, 105, 119, 120, 127, 128, 140, 141, 145–151, 161, 162, 165, 169, 175–183, 186–189
corepressors, of, 27, 29
Estrogen receptor loss, 40
- Everolimus, 166, 180, 184, 185, 188
- Extracellular matrix, 85–89, 91, 93, 122, 143, 146, 147
- F**
- Farnesyltransferase inhibitor, 17, 65, 180, 184, 187
- Faslodex, 6, 18, 30, 48, 54, 65, 92, 181
- Fibroblasts, 11, 18, 31, 72, 85–87, 89–93, 102, 144, 145, 152, 187
- Focal adhesion kinase, 150, 151
- Fulvestrant, 6, 8, 12, 13, 15, 16, 53, 54, 65, 66, 68, 70, 72, 74–76, 90, 91, 103, 141–146, 149, 165, 167, 169, 176, 179–181
resistance, 15, 65, 70, 90, 91, 103, 142, 144, 146
- G**
- Gefitinib, 8, 17, 18, 32, 65, 165, 167, 180, 182, 183, 185, 186, 188
- Geldanamycin, 114, 115, 117, 121, 123, 127
- Gene regulation, 27, 29
- Genomic response, 5
- Growth factor pathway switching, 17
- Growth factor receptors, 2, 4, 5, 8, 11, 13–17, 32, 34, 39, 42, 50, 52, 53, 64, 65, 69, 102, 146–149, 178–181, 187, 188
- Growth factor signaling, 1–9, 11–18, 32–34, 39, 53, 64, 75, 139–141, 163, 175, 177, 179, 181, 182, 189
- H**
- HDAC inhibitor, 55, 177
- Heat shock protein, 7, 118, 119, 121
inhibitors, 112
- Hedgehog (Hh), 103, 105
- Hepatocyte growth factor (HGF), 3, 15, 18, 69, 72, 85–87, 90, 144–146
- Histone, 29, 30, 73
code, 29
deacetylase, 4, 29, 33, 53, 55, 67, 105, 125, 177
deacetylation, 4, 29, 30, 33, 42, 53, 55, 67, 73, 74, 76, 105, 125, 177
methyltransferases, 29, 30, 34
- HSP70, 118
- HSP90, 111–129
inhibitors, 111–117, 120–129
isoforms, 112, 114, 121–123
post-translational modification of, 125
- Hypermethylation, 42, 51–55, 73, 74, 177
- Hypermethylation, of ER promoter, 42, 51–55
- I**
- IGFs, 85–87, 89
- Insulin growth factor 1 receptor (IGF1R), 65, 68, 87, 140, 179
- Interleukin 4 (IL4), 103
- Interleukin 6 (IL6), 85–88, 90
- Invasion, 65, 66, 70, 71, 87–90, 93, 114, 118, 119, 140–148, 151
- IPI-504, 115, 117
- K**
- Ki67, 40, 42, 188
- L**
- Lapatinib, 17, 32, 103, 177, 180, 182, 186, 187
- Letrozole, 167, 185–188
- Lymphocytes, 85–87, 90
- M**
- Macrophages, 85–88, 90, 93
- Macrophage stimulating protein, 87, 88
- Mammosphere, 99, 101, 103
- Membrane ruffling, 141
- Metalloproteinases, 87, 88
- Metastasis, 85–88, 92, 93, 114, 122, 140, 145

Methylation, 13, 29, 42, 53, 74–76, 161, 166, 177

Microarray, 18, 28, 29, 40, 52, 63, 64, 66, 68–70, 75, 90, 142, 178
 profiling, 40

Microvessel density, 104

Migration, 71, 87, 88, 90–92, 140–144, 146, 151, 152

Mitogen-activated protein kinase (MAPK), 4, 5, 8, 9, 11, 13, 14, 16, 32, 39, 40, 43–55, 65, 68, 161, 165–167, 177–180, 182, 187
 gene signature, 46

MTOR, 167, 169, 175, 188
 antagonist, 180, 187, 188
 inhibitor, 17, 167, 175, 184, 188

Myofibroblasts, 86

N

NCoR, 4, 30–34, 74, 177

Neoadjuvant, 101, 103, 179, 188

Neurosphere, 98, 99, 104

NF- κ B, 12, 13, 18, 47, 54, 67, 69, 70, 143

Non-genomic response, 5

Nuclear receptor, 28–30, 32
 coactivator, 4, 8, 30–32, 177
 corepressor, 4, 30–34, 74, 177

Nuclear transcription factors, 1, 3, 4, 16

O

Oestrogen deprivation, 6, 7, 11, 12, 53, 101, 145, 165, 169, 178, 179, 182, 186

Oestrogen receptor-alpha (ER α), 3, 27–29, 39, 40, 63, 64, 101, 161

Oestrogen receptor signaling, 13

Oestrogen response elements (ERE), 3, 4, 9, 28, 31, 44, 45, 54, 67, 71, 74, 89

P

P21^{CIP1}, 169

PARP-1, 34

PDK1, 162, 165, 166, 168–170

Phase III trials, 127, 181, 186, 188

Phase II studies, 127

PI3K, 5, 10, 11, 16, 17, 32, 64, 127, 128, 143, 147, 151, 168, 179, 187, 188

Primary human endothelial cells, 104

Progesterone receptor (PR)(PgR), 45, 54, 74, 91, 102, 177

Proteasome inhibitor, 116

Pure anti-oestrogen, 6, 90

R

RAD001, 167

Retaspimycin, 117

Rho, 10, 71, 142, 143

RhoE, 12, 71

RNA-induced silencing complex (RISC), 163, 164

RNA interference (RNAi), 13, 31, 161–170
 libraries, 164
 screen, 13, 161, 162, 164, 165, 167–170

RUNX3, 73

S

Selective oestrogen receptor modulators, 6–8, 14, 16, 31, 176

Signal transduction, 3, 5, 8, 9, 12, 17, 18, 43, 71, 128, 166, 169, 175, 179, 182
 inhibitors, 12, 18, 71, 166, 169, 175, 179, 182

SiRNA, 14, 43, 66, 70, 71, 74, 76, 112, 123, 124, 126, 146, 151, 152, 163–165, 169

Small molecule screen, 162, 167, 169, 170

SMRT, 30–34, 67, 74

SoFEA trials, 181

SRC-18, 16

Src, 9, 10, 13, 30, 33, 65, 69, 72, 76, 139, 140, 143, 147–152
 inhibitor, 152

Steroid signaling, membrane initiated, 5, 11

Stroma, 86, 88–92, 140, 147

Substrate mimetics, 112, 114, 126, 128

T

Tamoxifen, 6, 8–11, 13–15, 17, 18, 28, 30–32, 39, 41, 42, 48, 50, 51, 54, 64, 66, 68, 70, 71, 74–76, 89–92, 102, 103, 141–143, 145–151, 162–170, 176–182, 184–188
 resistance, 8–11, 14, 31, 65, 68, 75, 90, 103, 143, 146, 150, 165, 166, 170, 178, 182, 186
 sensitizer, 167, 168, 170

Tanespimycin, 115

Temsirolimus, 166, 180, 184, 185, 188

Tipifarnib, 180, 184, 185, 187

Transforming growth factor alpha (TGF α), 3, 87

Transforming growth factor beta (TGF β), 9, 87, 88, 147

Trastuzumab, 17, 18, 116, 127, 128, 177, 180, 182, 184–186

- Triciribine, 167, 168
Tumour associated fibroblasts, 85–93, 102
Tumour microenvironment, 85–93, 143, 144, 146, 147, 152
Tumour necrosis factor alpha (TNF α), 87, 88
Tumour-stroma interactions, 92, 145
Tumour suppressor, 14, 15, 18, 63, 64, 73, 75, 76
Tyrosine kinase inhibitor, 17, 116, 177, 180, 182, 186
- U**
UO126, 44, 45, 47–53
- V**
Vascular endothelial growth factor (VEGF), 3, 11, 13, 45, 67, 73, 87, 104, 151, 187
- X**
Xenografts, 53, 65, 92, 98, 100, 104, 116–121, 126, 127, 177, 178, 181, 182, 186, 187